# Dr. Reddy's Laboratories Limited (RDY)

> Source: Nexqual · https://nexqual.com/RDY · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Dr. Reddy's Laboratories Limited (RDY), nexqual.com/RDY" · informational, not investment advice.

**Price:** USD 13.21 (-0.15% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 13.21 · day 13.18–13.55 · 52w 11.36–15.67 · market cap null · NYQ

## Key facts
- Total return with dividends: 1Y -8.8% vs S&P 500 +13.4%; 5Y +12.8% vs S&P 500 +76.9%.
- Next earnings: 2026-10-23, EPS estimate USD —, revenue estimate $93.1B.

## Analysts
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Citigroup | Upgrade | Sell → Buy | $1040 → $1450 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -8.8% | +12.8% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -8.8% | +2.5% |
| Volatility (annualized) | 27.7% | 23.9% |
| Max drawdown | -26.0% (Jun 2026→Jul 2026) | -28.8% (Aug 2024→Jul 2026) |

## Peers (Drug Manufacturers - Specialty & Generic)
ELAN (Elanco Animal Health Incorporat) USD 22.52 -0.75% · NBIX (Neurocrine Biosciences, Inc.) USD 142.7 -0.41% · ALKS (Alkermes plc) USD 43.63 -1.24% · AMRX (Amneal Pharmaceuticals, Inc.) USD 20.38 -0.49% · HIMS (Hims & Hers Health, Inc.) USD 27.71 -4.87% · LNTH (Lantheus Holdings, Inc.) USD 99.8 -0.30%

## More
Full page: https://nexqual.com/RDY · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)

Named in RDY's own 20-F filed 2026-05-29 (https://www.sec.gov/Archives/edgar/data/1135951/000157587226000381/rdy0899_20f.htm):

| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | United Healthcare Services | "We support our local customers through our commercial offices in various markets, including Brazil, China, Europe, India, Japan, Mexico, the United States, United Arab Emirates and Russia with colleagues from regulatory …" |
| Customer | India | "We support our local customers through our commercial offices in various markets, including Brazil, China, Europe, India, Japan, Mexico, the United States, United Arab Emirates and Russia with colleagues from regulatory …" |
| Partner | Kunshan Rotam Reddy Pharmaceuticals Company | "Over the past several years, our joint venture called Kunshan Rotam Reddy Pharmaceuticals Company Limited ("KRRP") has commercialized several products." |
| Partner | Aurigene Pharmaceutical Services | "As part of his role, he heads our API business, the Aurigene Pharmaceutical Services Limited ("APSL") business, public health initiatives and business-to-business collaborations for our company." |
| Partner | Amazon (AMZN) | "He also played a critical role in driving various new growth initiatives, including the acquisition of over-the-counter brands; the development of our e-commerce presence on Amazon; and engaging with alternate channel pa…" |
| Partner | Haleon UK Enterprises | "For the limited markets still under transition, we continue to obtain distribution and related services under a Transitional Distribution Services Agreement with the Haleon Group until the remaining transfers are complet…" |
| Partner | Journey Medical Corp (DERM) | "For the year ended March 31, 2025, the license fees includes an amount of Rs.1,266 (U.S.$15) as a milestone payment receivable upon U.S. FDA approval of DFD 29, in accordance with the license and collaboration agreement …" |
| Competitor | Lonza | "Key competitors in India include Syngene International Ltd., Aragen Life Sciences, Sai Life Sciences and Piramal Pharma Ltd. Key competitors from outside India include Lonza Group, Patheon Inc., Catalent Inc., Cambrex In…" |
| Competitor | WuXi | "Key competitors in India include Syngene International Ltd., Aragen Life Sciences, Sai Life Sciences and Piramal Pharma Ltd. Key competitors from outside India include Lonza Group, Patheon Inc., Catalent Inc., Cambrex In…" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-12-31) | — | — | — | $93.09B | — |
| Next quarter (ends 2027-03-31) | — | — | — | $94.33B | — |
| Current fiscal year (ends 2027-03-31) | $46.22 | $43.85 | +5.4% | $354.04B | 2 |
| Next fiscal year (ends 2028-03-31) | $62.49 | $62.08 | +0.7% | $393.23B | 2 |